New Oncofetal Antigen for Human Pancreas

Expression of oncofoetal pancreatic antigens in hamster adult pancreas during experimental carcinogenesis

“…By the criterion of molecular weight assessed by acrylamide electrophoresis these oncofoetal antigens (5 were identified) seem to be different from human oncofoetal pancreatic antigens (Banwo et al, 1974, Gelder et al, 1978 or cancer-associated pancreatic antigens defined by polyclonal (Shimano et al, 1981) or monoclonal (Herlyn et al, 1982, Magnani et al, 1983 antibodies.…”

Enzyme-linked PNA lectin binding assay compared with CA19-9 and CEA radioimmunoassay as a diagnostic blood test for pancreatic cancer

“…These include carcinoembryonic antigen (CEA) (Gold & Freedman, 1965;Tatsuta et al, 1984), pancreatic oncofetal antigen (POA) (Banwo et al, 1974;Nishida et al, 1985), pancreatic cancer associated antigen (PCAA) (Chu et al, 1977;Loor et al, 1984), (Metzgar et al, 1984;Sawaku et al, 1986), CA19-9 (Koprowski et al, 1979;Haglund et al, 1986b), CA50 (Lindholm et al, 1983;Habib et al, 1986) and CA12-5 (Lehmann et al, 1984;Haglund, 1986). The most successful of these has proved to be CA19-9, which recognises the sialylated blood group Lewis antigen, which is expressed on a mucin secreted by the pancreatic tumour into the serum (Magnani et al, 1983).…”

Human pancreatic cancer associated antigen detected by monoclonal antibody.

“…The measurement of serum antigen level has been demonstrated to be one of the useful methods not only to detect the presence of malignancy but to monitor the disease state after each therapeutic procedure. A number of human pancreatic cancer-associated antigens have already been described and analyzed both experimentally and clinically using polyclonal xenoantisera (Banwo et al 1974 ; Schultz and Yunis 1976 ;Gelder et al 1978 ; Holyoke et al 1979 ;Hobbs 1980 ;Zamcheck 1981). However, the clinical application of these antigens for the early detection of pancreatic cancer has not yet been performed successfully because of the wide cross reactivity and the low sensitivity of the antisera (Banwo et al 1974 ; Schultz and Yunis 1976;Gelder et al 1978;Hobbs 1980).…”

“…A number of human pancreatic cancer-associated antigens have already been described and analyzed both experimentally and clinically using polyclonal xenoantisera (Banwo et al 1974 ; Schultz and Yunis 1976 ;Gelder et al 1978 ; Holyoke et al 1979 ;Hobbs 1980 ;Zamcheck 1981). However, the clinical application of these antigens for the early detection of pancreatic cancer has not yet been performed successfully because of the wide cross reactivity and the low sensitivity of the antisera (Banwo et al 1974 ; Schultz and Yunis 1976;Gelder et al 1978;Hobbs 1980). On the other hand, since the introduction of somatic cell hybridization (Kohler and Milstein 1975), a number of monoclonal antibodies against a variety of human tumors, such as melanoma ; Liao et al 1982;Natali et al 1982), lung cancer (Kasai et al 1981; Brown and Moore 1982; Mazauric et al 1982;Bernal and Speak 1984), breast cancer (Menard et al 1983; Papsidero et al 1983), colorectal cancer ; Atkinson et al 1982 ; Thompson et al 1983 ; Kaszubowski et al 1984), and prostate and bladder cancer (Starling et al 1982; Masuko et al 1985) have been produced.…”